Andrew Witty has taken a lot of flak over the past couple of years as GlaxoSmithKline Plc. lurched from one 'challenge' to another – from the bribery scandal in China and corruption allegations elsewhere, to a string of late-stage product failures, to a less than stellar uptake of its new respiratory franchise. But things are now on a steady footing and the UK-based pharma major is entering a growth phase, if the CEO's comments at the 34th annual JP Morgan Healthcare Conference on Jan. 13 are to betaken at face value.
At GSK's R&D update in November, rather a lot of incremental information on pipeline candidates was provided. Below, Scrip...





![Spotlight On RDCs, AOCs As Leading Novel Bioconjugates[Updated]](https://web.insights.norstella-labs.com/resizer/v2/3M7ZAWZOBNK7NG4A4WDOIFG6DU.jpg?smart=true&auth=392a1fdb3cfacb29445720c412410e598dbcc5f90f14857652cd498bd0faa0fb&width=400&height=225)
